As the prevalence of chronic kidney disease (CKD) and heart failure (HF) continues to rise, the exploration of therapies targeting shared pathways presents a promising avenue to alter the course of these interconnected diseases.
In a recent comprehensive review published in ESC Heart Failure, the intricate relationship between CKD and HF was underscored, shedding light on emerging therapies that hold the potential to revolutionize the management of patients grappling with both conditions.
The review brought to the forefront the frequent coexistence of CKD and HF, particularly prevalent among older adults. Alarmingly, approximately half of HF patients exhibit some degree of kidney disease, while one in four older adults with CKD also suffers from HF. This overlap significantly exacerbates outcomes, with comorbid CKD escalating mortality risk in HF patients by 32% to 51%, depending on the HF subtype.
Shared risk factors such as diabetes, obesity, and hypertension, alongside overlapping biological pathways, intricately link CKD and HF. Inflammation, endothelial dysfunction, neurohormonal activation, and fibrosis emerge as key players fueling the progression of both diseases.
The activation of the renin-angiotensin system (RAS) and sympathetic nervous system initially serves to maintain circulation in failing hearts or kidneys. However, chronic overactivation precipitates fibrosis, fluid overload, and adverse cardiac remodeling, exacerbating the conditions. Similarly, inappropriate activation of the mineralocorticoid receptor (MR) fosters oxidative stress, endothelial dysfunction, and tissue scarring in both the heart and kidneys.
This interplay sets the stage for a self-perpetuating cycle where deteriorating HF compromises kidney perfusion, while CKD accelerates cardiac dysfunction, creating a detrimental feedback loop.
Despite the significance of CKD in HF patients, the underdiagnosis of CKD remains a prevalent issue. While estimated glomerular filtration rate testing is standard, urine albumin-to-creatinine ratio (UACR) testing, a sensitive marker of early kidney damage, is underutilized. Suboptimal UACR testing rates (ranging from 4% to 53% in high-risk groups) contribute to a substantial number of undetected cases of kidney disease.
On the HF front, natriuretic peptide testing and echocardiography serve as cornerstones of diagnosis. However, interpreting biomarkers like NT-proBNP can be complicated by impaired kidney function. The integration of kidney and cardiac markers has the potential to enhance risk stratification and refine patient management.
Encouragingly, a range of therapies concurrently target CKD and HF. Renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and angiotensin-receptor-neprilysin inhibitors, have demonstrated efficacy in slowing CKD progression and reducing HF-related hospitalizations.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors such as dapagliflozin, empagliflozin, and canagliflozin have emerged as promising agents, offering robust benefits in reducing CKD progression and lowering the risk of HF hospitalizations, irrespective of diabetes status. Meta-analyses of extensive patient cohorts have highlighted the significant risk reduction associated with SGLT2 inhibitors in both kidney disease and cardiovascular outcomes.
Furthermore, mineralocorticoid receptor antagonists like finerenone, spironolactone, and eplerenone exhibit favorable effects by reducing fibrosis, inflammation, and proteinuria, thereby benefiting both the heart and kidneys.
A distinct class of treatments, initially developed for type 2 diabetes, known as glucagon-like peptide-1 (GLP-1) receptor agonists, not only aid in improving glycemic control and weight reduction but also offer anti-inflammatory and renal protective properties.
The amalgamation of therapies targeting the renin-angiotensin system, SGLT2 inhibition, mineralocorticoid receptor antagonism, and GLP-1 receptor agonism presents a compelling “quadruple therapy” approach that could markedly mitigate cardiovascular events and slow CKD progression, particularly in patients with diabetes and albuminuria.
While advancements in therapeutic strategies have been noteworthy, challenges persist. Polypharmacy is prevalent due to the overlapping conditions and associated comorbidities, posing hurdles in patient adherence, drug interactions, and cost implications. Moreover, there is a need to bridge the existing gaps in tailoring therapies across diverse HF phenotypes and CKD stages effectively.
The intricate landscape of treating patients with CKD and HF is further complicated by potential adverse drug interactions between medications for both conditions, reduced tolerance to certain drug classes, diuretic resistance, and compromised efficacy of implantable cardioverter defibrillator and resynchronization device therapy, emphasizing the need for a nuanced and individualized approach to patient care.
To navigate these challenges effectively, early diagnosis, enhanced biomarker-driven risk assessment, and personalized treatment regimens are imperative. Leveraging advancements in multi-omics and precision medicine holds promise in identifying patients most likely to benefit from specific therapeutic interventions.
In conclusion, the exploration of interconnected pathways and the evolution of novel therapies in CKD and HF represent a pivotal stride towards enhancing patient outcomes and refining the management of these intricate conditions. By unraveling the intricate web of shared risk factors and biological pathways, coupled with a tailored and holistic therapeutic approach, the landscape of CKD and HF management stands poised for transformative advancements.
Key Takeaways:
- Shared pathways and risk factors intricately link chronic kidney disease (CKD) and heart failure (HF).
- Therapies targeting both CKD and HF, such as RAS inhibitors and SGLT2 inhibitors, show promising results in improving patient outcomes.
- A comprehensive approach integrating multiple therapies may significantly reduce cardiovascular events and slow CKD progression.
- Challenges including polypharmacy, drug interactions, and personalized treatment tailoring necessitate a nuanced and individualized patient care approach.
Tags: filtration, bispecifics
Read more on ajmc.com